article = {GCCR-2020-1-105}
title = {Immune Checkpoint Myocarditis from Adjuvant Treatment of Melanoma}
journal = {Global Clinical Case Reports}
year = {2020}
issn = {}
doi = {http://dx.doi.org/10.31487/j.GCCR.2020.01.05}
url = {https://www.sciencerepository.org/immune-checkpoint-myocarditis-from-adjuvant-treatment-of-melanoma_GCCR-2020-1-105 
author = {John  Dasher,Lavanya  Kondapalli,Carrie Lenneman,}
keywords = {Immunotherapy, myocarditis, immune-related adverse events, cardiotoxicity}
abstract ={Immune checkpoint inhibitors (ICIs) are effective therapy for many metastatic cancers and are now being
used as adjuvant treatment for many stage III cancers to reduce the high risk of reoccurrence. ICIs activate
a patient’s own T-cells to fight cancer, but in some cases, immune-related adverse events (irAEs) with
inflammation of many organs can occur. Rare cases of myocarditis have been reported. More data is needed
to improve our ability to monitor, diagnose and treat irAEs.
}